SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Company is issuing 728,484 Class A ordinary shares to settle US$557,289.87 in accounts payable owed by its subsidiary WTP. The issuance represents 12.28% of outstanding shares at a price (US$0.765) that is 85% of the closing Nasdaq price, constituting a dilutive equity issuance to settle debt. This is a material capital event affecting existing shareholders' ownership percentage.
View raw filing on EDGAR →PS International Group Ltd. received an official Nasdaq deficiency letter dated August 12, 2026 for failure to maintain the minimum Market Value of Listed Securities (MVLS) of US$35 million and does not satisfy alternative continued listing criteria. The company has been granted a 180-calendar-day compliance period ending February 8, 2027, with explicit warning that failure to restore the required MVLS will result in formal delisting notification. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued trading status.
View raw filing on EDGAR →The 8-K discloses Citius Pharmaceuticals' fiscal third quarter 2026 financial results under Item 2.02 (Results of Operations and Financial Condition). The press release reports Q3 revenues of $1.5 million and nine-month revenues of $7.1 million from LYMPHIR commercial sales, along with detailed financial statements showing gross profit, operating expenses, and net loss figures. This is a standard quarterly earnings disclosure with attached financial tables and operational highlights.
View raw filing on EDGAR →On August 14, 2026, Citius Oncology, Inc. issued a press release announcing its results of operations for the third quarter of fiscal 2026, disclosing revenues of $1.5 million for Q3 2026 (compared to $0 in Q3 2025) and $7.1 million for the nine-month period, along with a net loss of $8.9 million for Q3 and condensed consolidated financial statements.
View raw filing on EDGAR →The filing discloses Allarity Therapeutics' financial results for the second quarter ended June 30, 2026, via a press release dated August 14, 2026. Item 2.02 explicitly covers "Results of Operations and Financial Condition," and the press release reports Q2 2026 financial metrics including cash position ($26.9 million), R&D expenses ($1.3 million), G&A expenses ($1.3 million), and comprehensive loss ($3.7 million), alongside operational highlights such as completion of Phase 3 manufacturing, patent grant, and CLIA certification. This is a standard quarterly earnings disclosure.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02, with the press release attached as Exhibit 99.1. The disclosure includes financial highlights (revenue, cash, gross profit, net loss, adjusted EBITDA), business highlights, and condensed consolidated balance sheet data. While the company reports declining revenue (11% decrease) and continued net losses, the disclosure is a routine quarterly financial results announcement material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →Thunder Bridge Capital Partners V is a special purpose acquisition company (SPAC) that consummated its initial public offering on August 14, 2026, raising $300.15 million in gross proceeds. Item 1.01 discloses entry into material definitive agreements in connection with the IPO, including the underwriting agreement and various governance documents. While technically an IPO, the filing's central disclosure under Item 1.01 emphasizes the company's formation and capitalization specifically "for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination." The $300.15 million trust account structure and the company's stated purpose align with ma_activity classification as the foundational capital-raising event enabling future M&A.
View raw filing on EDGAR →This disclosure describes the consummation of a blank-check company's IPO on August 10, 2026, generating $200 million in gross proceeds from the sale of 20 million units at $10.00 per unit, plus a concurrent $2.25 million private placement to the sponsor. While the event is clearly material to investors, it does not fit neatly into the standard 8-K taxonomy: it is neither an earnings release (no financial results), nor a traditional M&A activity (no business combination has occurred), nor a capital raise in the form of debt or dilutive equity issuance (the IPO itself is the primary capital event, but the units are the initial public offering structure rather than a secondary offering or PIPE). The filing is primarily informational about the IPO consummation and trust account mechanics, which is foundational to a SPAC's existence but does not align with the specific event types provided.
View raw filing on EDGAR →Actinium Pharmaceuticals received notice of non-compliance with NYSE American continued listing standards (Sections 1003(a)(ii) and (iii)) on May 27, 2026, submitted a compliance plan on June 18, 2026, and on August 12, 2026 received acceptance of that plan with a plan period through November 27, 2027. The company's stock continues to trade on NYSE American subject to compliance with the plan, with explicit warning that failure to regain compliance or make progress consistent with the plan may result in delisting proceedings.
View raw filing on EDGAR →HeartBeam entered into an At-The-Market (ATM) equity offering agreement on August 14, 2026, authorizing the sale of up to $25 million in common stock through Titan Partners Securities LLC. ATM offerings are a form of registered direct equity issuance that can be dilutive to existing shareholders. The filing explicitly references the shelf Registration Statement (Form S-3) and prospectus supplement, confirming this is a registered offering of equity securities that would materially affect investor assessment of capital structure and dilution risk.
View raw filing on EDGAR →MSP Recovery entered into multiple letter agreements creating new direct financial obligations totaling $0.16 million: $0.05 million and $0.06 million advances from Hazel Partners under its working capital credit facility (August 4 and August 13, 2026), and $0.05 million advances from VRM MSP Recovery Partners (August 3 and August 12, 2026). The cautionary language emphasizing these are 'standalone accommodations' and 'one-time advances' with no commitment for future funding suggests the company is in a tight liquidity position.
View raw filing on EDGAR →The disclosure describes entry into a material consulting agreement for marketing and advertising services with a $2,000,000 cash fee. While Item 1.01 typically covers M&A activity, this agreement is a material operational/strategic contract for investor relations and media distribution services. The substantial fee and three-month term make it material to investors, but it does not fit the specific categories of M&A, debt issuance, or other defined financial events—it is a material operational contract for services.
View raw filing on EDGAR →Item 4.01 discloses that Marcum LLP resigned as the Company's independent registered public accounting firm on June 3, 2026, following CBIZ CPAs' acquisition of Marcum's attest business effective November 1, 2024. The filing explicitly addresses auditor resignation and includes the required letter from the departing auditor (Exhibit 16.1), which are hallmarks of an auditor change disclosure under Item 4.01 of Form 8-K.
View raw filing on EDGAR →This exhibit is a Form 51-102F4 Business Acquisition Report disclosing Greenfire Resources' completed acquisition of all issued and outstanding Class A common shares of Connacher Oil and Gas Limited for $1.297 billion in cash on August 5, 2026. The acquisition of a material oil sands asset (Great Divide project) directly adjacent to Greenfire's existing Hangingstone Facilities, funded through $575 million bridge facility and $775 million rights offering, constitutes a material acquisition requiring disclosure under Item 1.01 of the 8-K taxonomy equivalent.
View raw filing on EDGAR →The filing discloses authID's financial results for Q2 2026 ended June 30, 2026, via a press release dated August 14, 2026, furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02. While the press release also mentions the Board's evaluation of strategic and financing alternatives, the primary disclosed event is the earnings release itself, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →VerifyMe issued a press release on August 14, 2026, disclosing financial results for Q2 2026 and the six-month period ended June 30, 2026. The filing includes consolidated balance sheets, statements of operations, and key financial metrics (revenue of $1.9M vs. $4.5M prior year, net loss of ($0.5)M, cash position of $5.1M). This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →This is a corporate update disclosing material operational and strategic progress across BTQ's four business lines (QCIM, QPerfect, QSSN, Bitcoin Quantum), including completion of the QPerfect acquisition, commercial pipeline expansion, and advancement toward production deployment of key products. While the document contains no discrete financial results, earnings figures, or formal periodic financial statements, it discloses material operational milestones and commercial progress that would affect a reasonable investor's assessment of the company's execution trajectory and market positioning in quantum technologies.
View raw filing on EDGAR →The auditor's review report contains an explicit "Emphasis - Material uncertainty related to going concern" section stating that current liabilities exceeded total assets by R$ 1,889 million (parent) and R$ 8,701 million (consolidated), with negative equity of R$ 12,586 million (parent) and R$ 13,087 million (consolidated). The report concludes that "a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern," which is the unmistakable language triggering this classification.
View raw filing on EDGAR →This is a comprehensive earnings release for Azul S.A.'s second quarter 2026 results, disclosing detailed financial and operating metrics including revenue (R$4.98 billion), EBITDA (R$510.1 million), net loss (R$1.04 billion), and key operational data. The filing explicitly states "Azul Reports 2Q26 Results" and presents consolidated financial statements with year-over-year comparisons, making it a material earnings disclosure that would affect investor assessment of the airline's financial performance and operational trajectory.
View raw filing on EDGAR →This is a quarterly earnings release for Braskem S.A. disclosing 2Q26 financial results. The document explicitly states "Braskem reports Recurring EBITDA of approximately US$1.0 billion in 2Q26" and provides detailed consolidated financial overview including revenue, COGS, EBITDA, and cash flow metrics across all business segments. The filing includes a conference call schedule and investor relations contact information typical of earnings announcements.
View raw filing on EDGAR →This is a press release announcing Sigma Lithium's second quarter 2026 financial results, disclosing record revenues of US$55 million, record EBITDA margin of 47%, and significant operational metrics including production volumes and cost reductions. The document explicitly states "announces the Company's results for the three months ended June 30, 2026" and includes detailed financial highlights, operational updates, and production guidance—all hallmarks of a quarterly earnings release. Material to investors as it demonstrates strong profitability and operational progress.
View raw filing on EDGAR →This 6-K furnishes SABESP's quarterly financial statements for the six-month period ended June 30, 2026, including consolidated and individual statements of financial position, income, comprehensive income, cash flows, and value added. The exhibit also includes an earnings release dated August 12, 2026 with 2Q26 results. As a periodic quarterly financial report (the foreign-issuer equivalent of a 10-Q), this is classified as periodic_quarterly rather than earnings_release, which is reserved for discrete press releases announcing results. The financial statements themselves are the primary disclosure here.
View raw filing on EDGAR →This 6-K furnishes an earnings conference call presentation for Braskem's 2Q26 results, dated August 14, 2026. The document discloses consolidated recurring EBITDA of US$1,043 million for 2Q26 (up from US$192 million in 1Q26), segment-by-segment performance metrics, cash flow analysis, and forward guidance on spreads and industry conditions. The presentation explicitly covers "2Q26 CONSOLIDATED PERFORMANCE" with detailed financial results and is titled "EARNINGS CONFERENCE CALL 2Q26," making it a discrete earnings event rather than a periodic financial report.
View raw filing on EDGAR →Jeffrey Zerillo, Senior Vice President of Operations, notified the Company of his retirement effective August 14, 2026. This is a clear executive departure — a named officer leaving his position. The filing discloses the departure date and his decision to retire from all positions held with the Company, making this a material event affecting the registrant's leadership structure.
View raw filing on EDGAR →The exhibit is a press release dated August 13, 2026, announcing Euroseas Ltd.'s financial results for Q2 2026 and the first half of 2026, including detailed revenue ($56.5M for Q2, $112.3M for H1), net income ($33.2M and $65.7M respectively), EPS ($4.77 basic for Q2), and operational metrics. The release also declares a quarterly dividend of $0.80 per share. This is a discrete earnings announcement, not a periodic financial report, and would materially affect investor assessment of the company's financial performance and capital allocation.
View raw filing on EDGAR →Capital Bancorp dismissed Elliott Davis, PLLC and engaged Crowe LLP as its independent registered public accounting firm effective August 14, 2026. This is a classic auditor change under Item 4.01. The filing discloses no disagreements or reportable events with the prior auditor (except a previously disclosed material weakness in internal controls), and the change was driven by the Audit Committee's determination to engage a larger firm with additional resources and industry specialization. This is material to investors as it affects the registrant's financial reporting oversight and audit quality.
View raw filing on EDGAR →Invesco Mortgage Capital Inc. declared a cash dividend of $0.12 per share of common stock for August 2026, with an ex-dividend date of August 25, 2026 and payment date of September 15, 2026. The filing also includes preliminary month-end financial data including book value, portfolio composition, and leverage metrics as supplemental context.
View raw filing on EDGAR →VirTra issued a press release on August 13, 2026 announcing financial results for Q2 and six months ended June 30, 2026, with detailed revenue, gross profit, net income, and EPS figures. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1. The disclosure shows material year-over-year declines (revenue down 35% for six months, net loss of $1.6M vs. prior year income of $1.4M), making this a material earnings release that would affect investor assessment of the company's financial performance.
View raw filing on EDGAR →This is a clear earnings release disclosing Q2 2026 and 1H 2026 financial results for BIO-key International. The press release (Exhibit 99.1) announces revenues of $1.9M in Q2'26 (up 13% YoY), gross margin improvement to 87%, and a 51% reduction in net loss to $(577K). The filing is made under Item 2.02 (Results of Operations and Financial Condition) and includes detailed financial statements and management commentary on performance and outlook.
View raw filing on EDGAR →Professional Diversity Network disclosed financial results for the three and six months ended June 30, 2026, including revenue, costs, net loss, balance sheet, and cash flow information via a press release attached as Exhibit 99.1.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 14, 2026 under Item 2.02. The press release (Exhibit 99.1) announces financial results including R&D expenses of $5.5M, G&A expenses of $2.1M, and a net loss of $7.6M for the quarter, along with unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports the company's quarterly financial performance and operational highlights including positive interim MIRACLE trial data.
View raw filing on EDGAR →Clene Inc. issued a press release on August 14, 2026, announcing its second quarter 2026 financial results for the quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets. The disclosure includes quarterly revenue, operating expenses, net loss of $13.4 million ($1.08 per share), and cash position of $9.7 million as of June 30, 2026. This is a standard earnings release filed under Item 2.02 with financial statements attached as Exhibit 99.1.
View raw filing on EDGAR →Track Group issued a press release on August 14, 2026, announcing financial results for the third fiscal quarter ended June 30, 2026. The disclosure includes detailed quarterly revenue ($9.09 million), net income ($22.44 million, driven primarily by a $23.46 million gain on troubled debt restructuring), earnings per share ($0.68 diluted), and non-GAAP metrics (Adjusted EBITDA of $1.47 million). The press release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings announcement under Item 2.02.
View raw filing on EDGAR →Byrna Technologies appointed retired U.S. Army Brigadier General Rose Lopez Keravuori to its Board of Directors effective August 10, 2026, and assigned her to a newly formed Enterprise Risk Management Committee. Concurrently, director Emily Rooney resigned, and the company dissolved its Product Safety Committee as part of a board governance restructuring.
View raw filing on EDGAR →This is a standard earnings release for Q2 2026 ended June 30, 2026, filed on August 14, 2026. The press release discloses quarterly financial results including net sales ($23.2M vs. $39.2M prior year), gross profit margins, SG&A expenses, net loss ($10.6M vs. $16.9M), and Adjusted EBITDA. The full text is furnished as Exhibit 99.1 and incorporated by reference in Item 2.02, which is the standard Item for results of operations and financial condition disclosures. Material to investors as it shows significant revenue decline and ongoing losses.
View raw filing on EDGAR →The Company and Carmell Regen settled litigation with Puritan, with parties agreeing to file a stipulation dismissing the case. The settlement is documented in a Settlement Agreement and involves material financial and operational consequences.
View raw filing on EDGAR →The Company issued $2.35 million in convertible notes (Initial Note of $1.25M and Additional Note of $1.1M) bearing 10% interest, maturing February 5, 2028, and secured by substantially all company assets. The notes include conversion rights, a 115% redemption premium, 15% default interest rate, and material covenants.
View raw filing on EDGAR →Scott Frisch resigned from the Board of Directors effective August 11, 2026. The resignation was not due to disagreement with the Company.
View raw filing on EDGAR →National Presto announced receipt of two significant defense contracts totaling $159.1 million: option awards under AMTEC's 40mm systems contract and a Spectra Technologies subcontract for Small Diameter Bomb warhead production. These are material operational/strategic business events—new contract awards that will drive future revenue and operations—but do not fit the specific categories of M&A, debt, equity issuance, or other named event types. The materiality is evident from the dollar magnitude ($159.1M) and the company's public announcement via press release.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) and year-to-date results. The Item 2.02 disclosure explicitly states "The LGL Group, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The filing includes detailed financial statements, revenue analysis, segment results, and management commentary on operational performance, making this a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →The filing discloses quarterly financial results for the six months ended June 30, 2026, with a press release issued on August 14, 2026. The press release includes condensed consolidated statements of operations, balance sheets, and supplemental financial information, presenting net loss of $3.7 million for the period. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and operational progress across its land development, commercial real estate, and agribusiness segments.
View raw filing on EDGAR →Teads received written notice from Nasdaq on August 11, 2026, that it failed to comply with Nasdaq Listing Rule 5450(a)(1) because its stock closing bid price has been below $1.00 per share for 30 consecutive business days. The company has been granted an initial 180-calendar-day compliance period (until February 8, 2027) to regain compliance, with the possibility of an additional 180-day period if it transfers to The Nasdaq Capital Market. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status and stock liquidity.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (three and six months ended June 30, 2026). The Item 2.02 disclosure explicitly states the company "issued a press release to report financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenue growth of 12.8% to $3.6 million, gross profit, operating expenses, and net loss figures, along with segment performance metrics and management commentary on business operations and strategy.
View raw filing on EDGAR →Item 2.02 discloses preliminary, unaudited operating information for Q2 2026 and July 2026 operating indicators in a shareholder update furnished as Exhibit 99.1. While labeled "preliminary" and "unaudited" rather than a formal earnings release, the disclosure provides quantitative and qualitative operating results (customer acquisition metrics, product sales volumes, cost reductions, subscription order percentages) that constitute a material update on financial condition and results of operations for the quarter ended June 30, 2026.
View raw filing on EDGAR →The filing discloses the sixth and final drawdown of $30,000 under an unsecured promissory note originally issued on March 16, 2026 by the Sponsor to fund the extension of the Business Combination deadline. While the note itself was previously disclosed, this Item 2.03 filing documents the creation and ongoing utilization of a direct financial obligation—a $180,000 promissory note with specific drawdown mechanics and repayment terms tied to the Company's liquidation or Business Combination. The disclosure of the sixth drawdown and extension of the Termination Date to September 17, 2026 represents a material financial event for this SPAC.
View raw filing on EDGAR →The filing discloses Q2 2026 financial results for Lantern Pharma via a press release dated August 14, 2026 (Item 2.02). The press release reports second quarter loss from operations of approximately $3.5 million (down 25% year-over-year), cash position of $7.4 million as of June 30, 2026, and gross proceeds of $4.4 million from a registered direct offering. While the filing also includes operational updates on clinical trials and the establishment of Open Medicine AI as a separate company, the primary disclosure mechanism is the earnings release attached as Exhibit 99.1.
View raw filing on EDGAR →The filing discloses the appointment of Wellington J. Reiter as an independent director to fill a newly created fifth board seat, effective August 11, 2026, along with his appointment to the Audit Committee. While compensatory arrangements (RSU grants totaling 210,045 units) are also disclosed, the principal action is the director appointment itself. This is material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →The 8-K discloses quarterly financial results for Q2 2026 under Item 2.02 (Results of Operation and Financial Condition). The press release reports revenue of $3.07 million (53% YoY growth), gross profit, operating loss of $1.72 million, and net loss of $1.75 million, along with segment performance and management commentary on strategic priorities. This is a standard earnings release disclosure material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →The filing discloses multiple governance events: resignation of two directors (Lei Sonny Wang and Thomas Morse), appointment of two new independent directors (Darren Kenney and Ronald J. Stauber), appointment of a new CFO (Yury Pyatigorsky), and formation of three standing board committees with written charters. While individual components could map to exec_departure and exec_appointment, the disclosure centers on a comprehensive board restructuring and governance framework enhancement undertaken to support the Company's NASDAQ listing application. This multi-faceted governance overhaul—combining director changes, committee formation, and executive leadership transition—is best classified as governance_other rather than a single executive event.
View raw filing on EDGAR →The 8-K discloses Safe Pro Group's Q2 2026 financial results under Item 2.02 (Results of Operations and Financial Condition), with a press release attached as Exhibit 99.1. The filing reports record revenue growth of 1,336% year-over-year ($1.33M vs. $92.8K), AI subsidiary revenue surge of 3,084%, and 75% AI gross margins, along with multiple government contract awards. This is a standard earnings release disclosure material to investors assessing the company's financial performance and growth trajectory.
View raw filing on EDGAR →